Cancer Research

The term cancer encompasses many diseases, all of which are characterized by uncontrolled cell proliferation and evolution of malignant cells that ignore the body’s signals to stop and multiply to form tumors in organs and tissues. At its core, cancer reflects a dynamic interplay between genetic mutations, epigenetic reprogramming, and complex interactions within the tumor microenvironment.

Cancer research encompasses a wide range of investigations focused on understanding, preventing, detecting, diagnosing, treating, and ultimately curing cancer. It involves studies ranging from basic laboratory experiments to transitional research and clinical trials involving patients. Particularly, this field has witnessed transformative breakthroughs in decoding disease mechanisms and translating insights into clinical strategies.

Recent advances include single-cell multi-omics technologies elucidating cellular heterogeneity within tumor-infiltrating lymphocytes (TILs) and cancer-associated fibroblasts (CAFs). Innovative diagnostic tools such as liquid biopsy integrating circulating tumor DNA (ctDNA) methylation profiling with fragmentomics, enable early detection of malignancies like breast and colorectal cancer with unprecedented sensitivity. Clinically, fourth-generation CAR-T therapies incorporating cytokine-armored technologies achieved durable remissions in refractory lymphomas, while mRNA vaccines targeting tumor-specific neoantigens show promise in early-phase trials for soild tumors. These collective advancements contribute to the growing population of cancer survivors, exemplified by 18 million individuals in the United States living with and beyond cancer.

Progress across cancer research stages relies critically on robust cellular models. At AcceGen, our comprehensive cell-based product portfolio is meticulously curated to support every stage of cancer research, from mechanistic discovery to translational and preclinical applications. Tumor cell lines serve as scalable systems for drug screening and resistance modeling. Primary cells, such as peripheral blood mononuclear cells (PBMCs) and CAFs, retain native phenotypic and molecular characteristics essential for studying immune evasion and tumor-stromal crosstalk. Immortalized cells offer stable platforms for high-throughput assays, while engineered reporter cell lines (e.g., HER2-overexpressing cancer lines or luciferase-tagged cell lines) facilitate real-time monitoring of metastasis and therapeutic efficacy.

For personalized medicine, induced pluripotent stem cells (iPSCs) enable generation of tumor organoids recapitulating patient-specific histopathology and drug responses, bridging in vitro and clinical contexts. miRNA agomir/antagomir libraries allow precise modulation of oncogenic or tumor-suppressive miRNAs. These tools accelerate target validation drug discovery, biomarker identification and precision oncology development. AcceGen is committed to equipping researchers with biologically relevant and technically versatile models to address the adaptive resilience of cancer and advance precise therapeutic management.